Robert J. Kreitman MD

AstraZeneca and MedImmune present results from Phase III clinical trial of moxetumomab pasudotox in patients with hairy cell leukaemia

Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence…

6 years ago